Prophylaxis versus preemptive protocols for CMV: do they impact graft survival?
Miller
G G
GG
Kaplan
B
B
D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects / Q000502:physiology*; D011183:Postoperative Complications / Q000517:prevention & control / Q000821:virology; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000998:Antiviral Agents